ARCHIVES

FDA Advisors Unanimously Turn Down GPC Biotech’s Orplatna for Prostate Cancer.

This article is from The Cancer Letter archive.

Vol. 33 No. 29 | July 27, 2007

Download PDF Visit The Full Archive

Related Articles

Broder Hopes To Help “Fundable: Centers, Stops Short Of Promising Compliance With All IOM Points

May 5, 1989

Ramucirumab Improves Overall Survival, Progression-Free Survival in Phase III Trial

October 26, 2012

In Brief: Panel Meeting Canceled; New Senior Executive Service Draws Enthusiastic Response At NCI

July 13, 1979

Emory Executive Objects to Report On Merit review

July 22, 1977

Funding Opportunities

October 4, 2002

Kidney Cancer Group Seeks Proposals; AACR Offers Award

November 17, 1995